Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

NCT01431794 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Stopped Study was terminated due to cease in manufacturing of study drug.

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: LDE225-600mg
DRUG: Gemcitabine
DRUG: nab-paclitaxel
DRUG: LDE225-400mg
DRUG: LDE225-800mg

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]